North China Pharmaceutical anticipates its net profit attributable to shareholders to surge to 123.5 million yuan in the first half of the year, marking a 72% year-on-year increase. Notably, non-recurring net profit stands at 119.4 million yuan, experiencing a remarkable 120% growth. This impressive performance is attributed to the company's comprehensive measures, including deepening budget control, implementing lean management practices, effectively reducing procurement costs and various expenses, and significantly enhancing profitability.